← Leaderboards
Michael Peter Vitek
Duke University
$14,740,646
Attributed
$14,740,646
Total exposure
21
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–20$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$14,740,646 · 21
By mechanism
R44$7,796,280 · 4
R01$3,266,773 · 3
R43$2,207,283 · 10
R41$842,604 · 3
P50$627,706 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Apolipoprotein E”
- Randall J Bateman · Washington University$84,991,900
- Eric M Reiman · Banner Health$54,703,271
- Jose A Luchsinger · Columbia University Health Sciences$53,467,373
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Susan M Landau · University Of California Berkeley$47,252,026
- Paul S. Aisen · Cognition Therapeutics, Inc.$44,864,980
Research focus
Apolipoprotein ELaboratory MousePharmaceutical PreparationsBaseDoseAnimalsClinical ResearchInflammationReportingPeptidesDisease /Disorder ModelMouse ModelAnti-InflammatoryAnti-Inflammatory AgentsResponseAmericanGenetically Modified AnimalsCellsAlzheimer'S DiseaseBrainBloodPerformanceNeurofibrillary TanglesFuture
Grant awards (42)
DFMO Therapy for Polycystic Kidney Disease$299,934
R41 · FY2020 · DK · contact PI
Novel Therapy for Huntington's Disease$240,750
R43 · FY2018 · NS · contact PI
Novel Orally-Available Prodrugs for Alzheimer's Disease$225,000
R43 · FY2015 · AG · contact PI
Antagonizing the SET Oncoprotein$225,000
R43 · FY2015 · CA · contact PI
Inhibitor #2 of Protein Phosphatase 2A (I2PP2A) and Asthma$268,220
R43 · FY2014 · HL · contact PI
Investigational Safety and Toxicity Studies of Subcutaneous COG1410 for Alzheimer$273,242
R43 · FY2013 · AG · contact PI
Small Molecule Screen for Apolipoprotein-E/Alzheimer's Disease$290,460
R01 · FY2012 · AG · contact PI
Novel COG Compounds to Treat Asthma$261,824
R43 · FY2012 · HL · contact PI
Small Molecule Screen for Apolipoprotein-E/Alzheimer's Disease$225,760
R01 · FY2011 · AG · contact PI
Neuroprotective Apolipoprotein-E Analogs Continuation$485,763
R44 · FY2010 · AG · contact PI
Small Molecule Screen for Apolipoprotein-E/Alzheimer's Disease$433,088
R01 · FY2010 · AG · contact PI
Neuroprotective Apolipoprotein-E Analogs Continuation$1,056,457
R44 · FY2009 · AG · contact PI
Neuroprotective Apolipoprotein-E Analogs Continuation$1,066,881
R44 · FY2008 · AG · contact PI
NEUROPROTECTIVE APOLIPOPROTEIN-E ANALOGS$346,126
R44 · FY2007 · AG · contact PI
Novel Intervention for Colitis$279,250
R41 · FY2007 · DK · contact PI
Novel Intervention for Amyloid-Induced Neuroinflammation$263,420
R41 · FY2007 · AG · contact PI
NEUROPROTECTIVE APOLIPOPROTEIN-E ANALOGS$692,721
R44 · FY2006 · AG · contact PI
Triple Transgenic Model of Alzheimer's Disease$361,605
R01 · FY2006 · AG · contact PI
Novel Immunological Modifer as a Tissue Protector$127,408
R43 · FY2006 · AI · contact PI
NEUROPROTECTIVE APOLIPOPROTEIN-E ANALOGS$372,182
R44 · FY2005 · AG
Triple Transgenic Model of Alzheimer's Disease$370,307
R01 · FY2005 · AG
IMPROVED ASSAYS FOR SPECIFICALLY MEASURING COLLAGENASE-3$513,946
R44 · FY2004 · AG
IDENTIFICATION OF NEUROPROTECTIVE APOE-MIMETICS$467,160
R44 · FY2004 · NS
Triple Transgenic Model of Alzheimer's Disease$370,307
R01 · FY2004 · AG
IMPROVED ASSAYS FOR SPECIFICALLY MEASURING COLLAGENASE-3$469,035
R44 · FY2003 · AG
IDENTIFICATION OF NEUROPROTECTIVE APOE-MIMETICS$467,160
R44 · FY2003 · NS
Triple Transgenic Model of Alzheimer's Disease$370,307
R01 · FY2003 · AG
NOVEL INHIBITORS OF BRAIN ISCHEMIA$284,008
R43 · FY2003 · NS
IDENTIFICATION OF NEUROPROTECTIVE APOE-MIMETICS$522,445
R44 · FY2002 · NS
IMPROVED ASSAYS FOR SPECIFICALLY MEASURING COLLAGENASE-3$430,005
R44 · FY2002 · AG
Triple Transgenic Model of Alzheimer's Disease$367,688
R01 · FY2002 · AG
NEUROPROTECTIVE APOLIPOPROTEIN-E ANALOGS$201,831
R43 · FY2002 · AG
OXIDATIVE STRESS IN ALZHEIMER'S DISEASE$0
P50 · FY2002 · AG
OXIDATIVE STRESS IN ALZHEIMER'S DISEASE$0
P50 · FY2002 · AG
MUTATED TAU GENES AND NEUROFIBRILLARY TANGLE PATHOLOGY$457,372
R44 · FY2001 · AG
OXIDATIVE STRESS IN ALZHEIMER'S DISEASE$313,853
P50 · FY2001 · AG
ANIMAL MODEL OF ALZHEIMERS DISEASE PATHOLOGY$241,397
R01 · FY2001 · AG
OXIDATIVE STRESS IN ALZHEIMER'S DISEASE$0
P50 · FY2001 · AG
MUTATED TAU GENES AND NEUROFIBRILLARY TANGLE PATHOLOGY$449,027
R44 · FY2000 · AG
OXIDATIVE STRESS IN ALZHEIMER'S DISEASE$313,853
P50 · FY2000 · AG
ANIMAL MODEL OF ALZHEIMERS DISEASE PATHOLOGY$235,854
R01 · FY2000 · AG
IDENTIFICATION OF NEUROPROTECTIVE APOE-MIMETICS$100,000
R43 · FY2000 · AG